Eli Lilly’s alopecia drug Olumiant off to positive start with doctors, Spherix research finds
Eli Lilly’s alopecia areata drug is off to a good start with dermatologists. So good, in fact, that the launch of Olumiant in alopecia looks a lot like the initial positive launch of Sanofi and Regeneron’s Dupixent, according to launch tracking data from Spherix Global Insights.
Spherix benchmarked Olumiant against Dupixent’s launch approval in atopic dermatitis in part because there are no other candidates in alopecia, said Gianna Melendez, who heads dermatology at Spherix. Olumiant also compares similarly to Dupixent as a first biologic in the category, along with an accompanying level of excitement and buzz around it.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.